Vociprotafib

Vociprotafib
Clinical data
Drug class	SHP2 inhibitor
Identifiers
	IUPAC name [6-[(2-amino-3-chloro-4-pyridinyl)sulfanyl]-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl]methanol;
CAS Number	2172652-48-9 ;
PubChem CID	134182831 ;
Chemical and physical data
Formula	C20H27ClN6O2S
Molar mass	450.99 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES C[C@H]1[C@H](C2(CCN(CC2)C3=NC(=C(N=C3CO)SC4=C(C(=NC=C4)N)Cl)C)CO1)N;
	InChI InChI=1S/C20H27ClN6O2S/c1-11-19(30-14-3-6-24-17(23)15(14)21)26-13(9-28)18(25-11)27-7-4-20(5-8-27)10-29-12(2)16(20)22/h3,6,12,16,28H,4-5,7-10,22H2,1-2H3,(H2,23,24)/t12-,16+/m0/s1; Key:HISJAYUQVHMWTA-BLLLJJGKSA-N;

Last updated February 01, 2026

Vociprotafib (RMC-4630) is a drug that acts as an inhibitor of the protein tyrosine phosphatase enzyme SHP-2 (PTPN11). It has been researched for the treatment of cancer and has seen some early stage clinical trials in humans.^[1]^[2]^[3]

References

↑ Smith JA, Singh M, Nichols RJ, Koltun ES, Yang YC, Wildes DP, et al. (2020). "Abstract 1943: SHP2 inhibition as the backbone of targeted therapy combinations for the treatment of cancers driven by oncogenic mutations in the RAS pathway". Cancer Research. 80 (16_Supplement): 1943. doi:10.1158/1538-7445.AM2020-1943.
↑ Perrone C, Angioli R, Luvero D, Giannini A, Di Donato V, Cuccu I, et al. (July 2024). "Targeting BRAF pathway in low-grade serous ovarian cancer". Journal of Gynecologic Oncology. 35 (4) e104. doi:10.3802/jgo.2024.35.e104. PMC 11262891 . PMID 38768941.
↑ Luo J, Villaruz LC (November 2025). "Combined SHP2 and KRAS^G12C inhibitor therapy in patients with non-small-cell lung cancer". The Lancet. Respiratory Medicine. doi:10.1016/S2213-2600(25)00298-X. PMID 41325754.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] Smith JA, Singh M, Nichols RJ, Koltun ES, Yang YC, Wildes DP, et al. (2020). "Abstract 1943: SHP2 inhibition as the backbone of targeted therapy combinations for the treatment of cancers driven by oncogenic mutations in the RAS pathway". Cancer Research. 80 (16_Supplement): 1943. doi:10.1158/1538-7445.AM2020-1943.

[2] Perrone C, Angioli R, Luvero D, Giannini A, Di Donato V, Cuccu I, et al. (July 2024). "Targeting BRAF pathway in low-grade serous ovarian cancer". Journal of Gynecologic Oncology. 35 (4) e104. doi:10.3802/jgo.2024.35.e104. PMC 11262891 . PMID 38768941.

[3] Luo J, Villaruz LC (November 2025). "Combined SHP2 and KRAS^G12C inhibitor therapy in patients with non-small-cell lung cancer". The Lancet. Respiratory Medicine. doi:10.1016/S2213-2600(25)00298-X. PMID 41325754.

[1]

[2]

[3]